According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis.
Clinical Ink, a provider of eSource solutions for clinical trials, announced that CentrosHealth, a mobile patient engagement platform, now includes streamlined connectivity for a wide range of medical devices. This new platform was developed with cooperation from Novartis and PPD, who are also supporting a pilot clinical study before broad commercial use. According to the release, PPD noted that wearable technology will have the potential to benefit Novartis and its other clients because of the integration with the technologies patients use on a daily basis.
